Example of buyouts at huge premiums! Could this be ERHC soon?
1. A 200% Buyout Premium From Private Equity (ANL)
Posted: December 10, 2008 at 2:13 pm
Print Email Subscribe Free Newsletter Follow us on Twitter American Land Lease Inc. (NYSE: ANL) is perhaps one of the more unusual plays seen yet in private equity acquisitions. Despite a 200% premium, the more odd part of "for how much" is the "why"….. American Land Lease Inc. stock closed at $3.90 yesterday, yet it has signed an agreement to be acquired by affiliates of Green Courte Partners for $14.20 per share.
2. Intercell AG announced late Monday a deal to acquire Iomai (IOMI Quote) in a stock and cash transaction valuing the biopharmaceutical company at roughly $189 million.
More on Biotech Targacept Depression Drug Hits the MarkHemispherx Not Among 4 to Get H1N1 Flu ContractsCell Therapeutics Has to Sprint to Reach TargetBiotech Stock Mailbag: Chelsea TherapeuticsRigel's R788 Drug Improves RA SymptomsDendreon: Provenge to Survive Health ReformAryx Keeps Biotech Investors HumbleArena Pharma Raising Cash, Again?Elan Does Right by Its ShareholdersFDA Seeks More Data on Blood Cancer Drug Market Activity Merck & Company Incorporated| MRK UPNovartis AG ADS| NVS DOWNAustria-based Intercell has agreed to pay $6.60 a share for Iomi -- a 126% premium to the stock's closing price Monday. The news sent Iomai shares soaring more than 100% in off-hours trading to open up Tuesday $3.29, or 112.7%, higher at $6.21.
3. Thermage has received an unsolicited takeover bid from an as-yet-unnamed third party calling for the acquisition of all outstanding shares at $5.50 a piece. That bid, to be paid in cash or a combination of cash and stock (it appears to be a public company) represents an 82% premium over yesterday’s closing price.
4. Barrier Therapeutics Huge Premium Buyout (BTRX)
June 23, 2008 · Filed Under General
Barrier Therapeutics, Inc. (NASDAQ:BTRX) is seeing shares surge after it has signed a merger agreement with Stiefel Laboratories, Inc., the world’s largest independent pharmaceutical company specializing in dermatology.
Stiefel Laboratories will purchase all of the outstanding stock of Barrier Therapeutics in a cash buyout valued at $4.15 per share. This price is a 73% premium to Barrier’s average closing price for the past 30 days and is more than a 100% premium to Friday’s close.
5. Tercica: The huge premium biotech mergers continue (TRCA)
June 5, 2008 · Filed Under General
Tercica, Inc. (NASDAQ: TRCA) is another small cap biotech that has received a huge premium acquisition from a foreign buyer. This buyout is a 104% premium to the prior close and a 74% premium to the 3-month average.
6. United Technologies Corp. (NYSE: UTX) has offered to acquire Diebold, Inc. (NYSE: DBD) for $40.00 per share in cash, which is a total enterprise value of approximately $3 billion. To top it off, this represents roughly a 66% premium to Friday's close of $24.12. The full release is here.
Mike
